Biodegradable Cisplatin-Eluting Tracheal Stent for Malignant Airway Obstruction

Chao, Yin‐Kai; Liu, Kuo‐Sheng; Wang, Yichuan; Huang, Yen-Lin; Liu, Shih‐Jung

doi:10.1378/chest.12-2282

Cited by 75 publications

(55 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drug loading did not increase with increase the concentration of sirolimus in solution, suggesting a saturation effect. Kong et al [16] reported that the optimal paclitaxel : stent coating ratio was 1:20, while Yin-Kai Chao et al [17] determined that the optimal cisplatin : coating ratio was 1:9. These differences may be related to differences in solubilities of drugs.…”

Section: Discussionmentioning

confidence: 99%

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Wang¹,

Chen²,

Lin³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Wang¹,

Chen²,

Lin³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Drug-eluting/BD stents have also been studied in gastrointestinal diseases [42]. In vitro and animal studies have been conducted as well with BD tracheal stents either coated with dexamethasone [43,44], cisplatin [45], or with mitomycin C (MMC) [46]. Zilberman et al [43,44] incorporated dexamethasone in a PLLA stent and showed that the cumulative release of dexamethasone from the stents was linear.…”

Section: Research and Medical Applications Of Degradable Biomaterialsmentioning

confidence: 99%

“…Drug incorporation had a minor effect on the initial stent strength. Chao et al [45] studied a degradable stent made of PCL coated with polylactide-polyglycolide copolymer and cisplatin. Kong et al [47] studied, in vitro, the PLGA tracheal stent loaded with paclitaxel and demonstrated a favorable surface morphology as well as sustained and effective drug release behavior.…”

Section: Research and Medical Applications Of Degradable Biomaterialsmentioning

confidence: 99%

See 1 more Smart Citation

Biodegradable Airway Stents - Bench to Bedside: A Comprehensive Review

Dutau¹,

Musani

Laroumagne³

et al. 2015

Respiration

View full text Add to dashboard Cite

Airway stents are indicated to treat symptomatic narrowing or to close fistulas of the central airways. They are generally divided into two types: the silicone stents and the metallic stents. Unlike in malignancies, removability is a major objective of temporary stenting in benign conditions, which poses the challenge of a new rigid bronchoscopic procedure under general anesthesia and stent removal with all its attendant risks and costs. The concept of a biodegradable (BD) stent that could maintain the patency of an airway for a predetermined duration of time is very appealing. These BD stents would gradually degrade and eventually vanish from the airway once they are no longer needed. Such stents are currently an area of intense research. Another very promising concept of drug delivery with such stents is also a very exciting area of current research. The aim of this comprehensive review is to discuss all pertinent available literature on the use of BD materials in various clinical applications and to extensively review all animal and humans trials involving BD airway stents.

show abstract

“…The semi-crystalline nature and significant elasticity at room temperature have rendered PCL unsuitable for fracture fixation implants in the orthopedic field. [23][24][25] However, many publications have described the experimental application of PCL as a scaffold to fill bone gaps and to provide osteoconduction in bone engineering. 26 We expanded the experimental application of PCL in this study in which it was used as a circumferential scaffold around the fracture site that mimicked the periosteum and provided elastic strength for fracture fragment fixation.…”

mentioning

confidence: 99%

A bio-artificial poly([D,L]-lactide-co-glycolide) drug-eluting nanofibrous periosteum for segmental long bone open fractures with significant periosteal stripping injuries

Chou¹,

Cheng²,

Hsu³

et al. 2016

IJN

Self Cite

View full text Add to dashboard Cite

Biodegradable poly([ d,l ]-lactide-co-glycolide) (PLGA) nanofibrous membrane embedded with two drug-to-polymer weight ratios, namely 1:3 and 1:6, which comprised PLGA 180 mg, lidocaine 20 mg, vancomycin 20 mg, and ceftazidime 20 mg, and PLGA 360 mg, lidocaine 20 mg, vancomycin 20 mg, and ceftazidime 20 mg, respectively, was produced as an artificial periosteum in the treatment of segmental femoral fractures. The nanofibrous membrane’s drug release behavior was assessed in vitro using high-performance liquid chromatography and the disk-diffusion method. A femoral segmental fracture model with intramedullary Kirschner-wire fixation was established for the in vivo rabbit activity study. Twenty-four rabbits were divided into two groups. Twelve rabbits in group A underwent femoral fracture fixation only, and 12 rabbits in group B underwent femoral fracture fixation and were administered the drug-loaded nanofibers. Radiographs obtained at 2, 6, and 12 weeks postoperatively were used to assess the bone unions. The total activity counts in animal behavior cages were also examined to evaluate the clinical performance of the rabbits. After the animals were euthanized, both femoral shafts were harvested and assessed for their torque strengths and toughness. The daily in vitro release curve for lidocaine showed that the nanofibers eluted effective levels of lidocaine for longer than 3 weeks. The bioactivity studies of vancomycin and ceftazidime showed that both antibiotics had effective and sustained bactericidal capacities for over 30 days. The findings from the in vivo animal activity study suggested that the rabbits with the artificial drug-eluting periosteum exhibited statistically increased levels of activity and better clinical performance outcomes compared with the rabbits without the artificial periosteum. In conclusion, this artificial drug-eluting periosteum may eventually be used for the treatment of open fractures.

show abstract

Biodegradable Cisplatin-Eluting Tracheal Stent for Malignant Airway Obstruction

Cited by 75 publications

References 17 publications

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Biodegradable Airway Stents - Bench to Bedside: A Comprehensive Review

A bio-artificial poly([D,L]-lactide-co-glycolide) drug-eluting nanofibrous periosteum for segmental long bone open fractures with significant periosteal stripping injuries

Contact Info

Product

Resources

About